Using this model, we could induce tumours by outcrossing the stock to a neutral control (UAS-luciferase) or to UAS-RNAi lines targeting Dgk or serotonin receptor genes and, by comparison, assess the impact on tumour size. The gene discussed is DGKB; the disease is neoplasm.